Benzinga · Oct 27, 2026
Datavault AI Stock Crashes — Financials Cannot Be Trusted: What You Need to Know
Datavault AI shares plunge nearly 40% after invalidating financial statements tied to a $150M Bitcoin deal.
NASDAQ · SCLX
Scilex Holding Company
Healthcare · Drug Manufacturers - General
$1.85
Down-$0.21 (-10.19%)
Updated Nov 2, 2026, 12:41 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 144.1M
- P/E ratio
- -0.52
- Dividend yield
- 0.00%
- 52-week range
- $1.83 – $27.00
- Volume
- 49.88K
- Avg. volume
- 202.34K
Price performance · SCLX
SCLX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
SCLX closed at $1.85 after 20 trading sessions, down 51.57% for the selected period.
- Last close
- $1.85
- Period change
- -51.57%
- Period low
- $1.85
- Period high
- $3.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $2.05 | $2.0638 | $1.83 | $1.85 | 49.88K |
| Oct 29, 2026 | $2.09 | $2.17 | $2.05 | $2.06 | 7.39K |
| Oct 28, 2026 | $2.01 | $2.10 | $2.01 | $2.09 | 17.02K |
| Oct 27, 2026 | $2.32 | $2.34 | $2.01 | $2.05 | 99.28K |
| Oct 26, 2026 | $2.35 | $2.40 | $2.28 | $2.33 | 47.85K |
| Oct 23, 2026 | $2.44 | $2.48 | $2.27 | $2.35 | 35.22K |
| Oct 22, 2026 | $2.56 | $2.60 | $2.449 | $2.47 | 33.42K |
| Oct 21, 2026 | $2.51 | $2.62 | $2.51 | $2.56 | 25.89K |
| Oct 20, 2026 | $2.55 | $2.68 | $2.52 | $2.53 | 35.74K |
| Oct 19, 2026 | $2.81 | $2.81 | $2.518 | $2.57 | 52.15K |
| Oct 16, 2026 | $2.82 | $2.8903 | $2.77 | $2.83 | 29.52K |
| Oct 15, 2026 | $2.83 | $2.85 | $2.77 | $2.82 | 12.54K |
| Oct 14, 2026 | $2.88 | $2.95 | $2.81 | $2.85 | 26.72K |
| Oct 13, 2026 | $2.81 | $3.225 | $2.79 | $2.88 | 33.97K |
| Oct 12, 2026 | $2.92 | $2.95 | $2.80 | $2.80 | 33.84K |
| Oct 9, 2026 | $2.96 | $3.1099 | $2.86 | $2.92 | 49.71K |
| Oct 8, 2026 | $3.49 | $3.5922 | $2.90 | $2.96 | 140.98K |
| Oct 7, 2026 | $3.90 | $3.90 | $3.445 | $3.49 | 82.15K |
| Oct 6, 2026 | $3.87 | $4.05 | $3.79 | $3.96 | 57.88K |
| Oct 5, 2026 | $4.13 | $4.49 | $3.81 | $3.82 | 59.62K |
Latest SCLX news
The latest Smart Investors Daily articles mentioning SCLX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SCLX research
Overview
Company profile and research snapshot.
Company profile
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 11, 2025 | D. Boral Capital | Hold | — |
| Apr 2, 2025 | D. Boral Capital | Buy | — |
| Feb 28, 2025 | D. Boral Capital | Buy | — |
| Jan 27, 2025 | D. Boral Capital | Buy | — |
| Oct 21, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 20, 2026
U.S. District Court Grants Motion To Compel Arbitration, Stay All Court Proceeds Brought Against St. James Bank & Trust Company, Omega & Corinth Group, And Marc Wade By Scilex Holding
The St. James Bank & Trust Company Ltd. ("St. James"), Omega & Corinth Group Ltd. and Marc Wade today announced that the U.S. District Court has granted their motion to compel arbitration and stay all
Yahoo · Jul 7, 2026
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
PALO ALTO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies, today announced the signing of a binding term sheet with iHolding Group LLP (“iHolding”), a private investment group headquartered in Almaty, Republic of Kazakhstan. The term sheet contemplates that iHolding will purchase $100,000,000 o
Benzinga · Jul 7, 2026
Scilex Portfolio Company Semnur Pharmaceuticals Receives $100M Investment From iHolding In 10M Newly Issued Shares At $10 Per Share
Semnur Pharmaceuticals, Inc. ("Semnur" or the "Company") (OTC:SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
